SG11202106348QA - Human alpha-galactosidase variants - Google Patents
Human alpha-galactosidase variantsInfo
- Publication number
- SG11202106348QA SG11202106348QA SG11202106348QA SG11202106348QA SG11202106348QA SG 11202106348Q A SG11202106348Q A SG 11202106348QA SG 11202106348Q A SG11202106348Q A SG 11202106348QA SG 11202106348Q A SG11202106348Q A SG 11202106348QA SG 11202106348Q A SG11202106348Q A SG 11202106348QA
- Authority
- SG
- Singapore
- Prior art keywords
- human alpha
- galactosidase
- variants
- galactosidase variants
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782553P | 2018-12-20 | 2018-12-20 | |
| PCT/US2019/067493 WO2020132252A2 (en) | 2018-12-20 | 2019-12-19 | Human alpha-galactosidase variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106348QA true SG11202106348QA (en) | 2021-07-29 |
Family
ID=71099305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106348QA SG11202106348QA (en) | 2018-12-20 | 2019-12-19 | Human alpha-galactosidase variants |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11427813B2 (en) |
| EP (1) | EP3898960A4 (en) |
| JP (1) | JP2022515742A (en) |
| KR (1) | KR20210106537A (en) |
| CN (1) | CN113544268A (en) |
| AU (1) | AU2019403323A1 (en) |
| BR (1) | BR112021011750A2 (en) |
| CA (1) | CA3123598A1 (en) |
| CO (1) | CO2021009297A2 (en) |
| EA (1) | EA202191735A1 (en) |
| IL (1) | IL284133A (en) |
| MX (1) | MX2021007552A (en) |
| PH (1) | PH12021551372A1 (en) |
| SG (1) | SG11202106348QA (en) |
| WO (1) | WO2020132252A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3237621T3 (en) * | 2014-12-22 | 2023-06-19 | Codexis Inc | VARIANTS OF HUMAN ALPHA-GALACTOSIDASE |
| EA202191735A1 (en) | 2018-12-20 | 2021-11-24 | Кодексис, Инк. | HUMAN ALPHA-GALACTOSIDASE OPTIONS |
| CA3209673A1 (en) * | 2021-02-26 | 2022-09-01 | Rizwana ISLAM | Composition and methods for the treatment of fabry disease |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356804A (en) | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| EP0777737B1 (en) | 1994-06-30 | 2005-05-04 | Novozymes Biotech, Inc. | Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein |
| FI104465B (en) | 1995-06-14 | 2000-02-15 | Valio Oy | Protein hydrolyzates for the treatment and prevention of allergies and their preparation and use |
| US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
| US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| HU230275B1 (en) | 1996-09-13 | 2015-11-30 | Shire Human Genetic Therapies, Inc | Method for producing purified human alpha galactosidase a compositions; pharmaceutical compositions comprising said purified compositions for use in treating disorders originating from alpha galactosidase a deficiency |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| AU743305C (en) | 1997-01-17 | 2006-03-30 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| AU746786B2 (en) | 1997-12-08 | 2002-05-02 | California Institute Of Technology | Method for creating polynucleotide and polypeptide sequences |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| JP4221100B2 (en) | 1999-01-13 | 2009-02-12 | エルピーダメモリ株式会社 | Semiconductor device |
| US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| US6917882B2 (en) | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
| EP1072010B1 (en) | 1999-01-19 | 2010-04-21 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US7702464B1 (en) | 2001-08-21 | 2010-04-20 | Maxygen, Inc. | Method and apparatus for codon determining |
| CA2364997A1 (en) | 1999-03-05 | 2000-09-08 | Maxygen, Inc. | Encryption of traits using split gene sequences |
| US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
| US6519065B1 (en) | 1999-11-05 | 2003-02-11 | Jds Fitel Inc. | Chromatic dispersion compensation device |
| AU4964101A (en) | 2000-03-30 | 2001-10-15 | Maxygen Inc | In silico cross-over site selection |
| US7747391B2 (en) | 2002-03-01 | 2010-06-29 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| EP2278509B1 (en) | 2002-03-01 | 2014-11-19 | Codexis Mayflower Holdings, LLC | Methods, systems, and software for identifying functional biomolecules |
| US20050084907A1 (en) | 2002-03-01 | 2005-04-21 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| JP4851687B2 (en) | 2002-03-09 | 2012-01-11 | マキシジェン， インコーポレイテッド | Crossover optimization for directed evolution |
| BRPI0309665B8 (en) | 2002-04-25 | 2021-05-25 | Transkaryotic Therapies Inc | method for analyzing an alpha-galactosidase preparation a |
| US20090038023A1 (en) | 2005-03-10 | 2009-02-05 | Verenium Corporation | Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| US8768871B2 (en) | 2008-02-12 | 2014-07-01 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
| DK2250595T3 (en) | 2008-02-12 | 2017-09-04 | Codexis Inc | PROCEDURE FOR SELECTING AN OPTIMIZED VARIETY OF VARIETIES |
| US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| EP2285958B1 (en) | 2008-06-13 | 2016-03-09 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| US8383346B2 (en) | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
| US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| US9593326B2 (en) | 2009-12-09 | 2017-03-14 | Codexis, Inc. | Protein variant generation by region shuffling |
| US8876066B1 (en) | 2009-12-17 | 2014-11-04 | Progressive Fastening, Inc. | Hanger with bolt closures |
| EP3025728B1 (en) | 2010-02-04 | 2018-08-08 | BioMarin Pharmaceutical Inc. | Method for purifying prokaryotic phenylalanine ammonia-lyase variants |
| HUE030959T2 (en) | 2010-03-02 | 2017-06-28 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
| EP4043025A1 (en) | 2011-06-08 | 2022-08-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| US20150050658A1 (en) | 2012-03-15 | 2015-02-19 | Codexix, Inc. | Gene shuffling methods |
| US9957495B2 (en) | 2012-04-18 | 2018-05-01 | Vib Vzw | Means and methods for generating improved proteins |
| KR102215219B1 (en) | 2013-01-31 | 2021-02-16 | 코덱시스, 인코포레이티드 | Methods, systems, and software for identifying bio-molecules using models of multiplicative form |
| SG11201601695WA (en) | 2013-09-27 | 2016-04-28 | Codexis Inc | Automated screening of enzyme variants |
| JP6309086B2 (en) | 2013-09-27 | 2018-04-11 | コデクシス， インコーポレイテッド | Structure-based predictive modeling |
| DK3237621T3 (en) | 2014-12-22 | 2023-06-19 | Codexis Inc | VARIANTS OF HUMAN ALPHA-GALACTOSIDASE |
| US20170051267A1 (en) * | 2015-08-20 | 2017-02-23 | Research Foundation Of The City University Of New York | Novel alpha-galactosidase a derivatives |
| EA202191735A1 (en) | 2018-12-20 | 2021-11-24 | Кодексис, Инк. | HUMAN ALPHA-GALACTOSIDASE OPTIONS |
| MX2022001623A (en) * | 2019-08-07 | 2022-03-02 | Amicus Therapeutics Inc | Methods of treating fabry disease in patients having a mutation in the gla gene. |
| CN116096898A (en) | 2020-02-28 | 2023-05-09 | 科德克希思公司 | Human alpha galactosidase variants |
-
2019
- 2019-12-19 EA EA202191735A patent/EA202191735A1/en unknown
- 2019-12-19 CN CN201980092718.9A patent/CN113544268A/en active Pending
- 2019-12-19 JP JP2021535658A patent/JP2022515742A/en active Pending
- 2019-12-19 EP EP19897710.0A patent/EP3898960A4/en active Pending
- 2019-12-19 MX MX2021007552A patent/MX2021007552A/en unknown
- 2019-12-19 KR KR1020217023026A patent/KR20210106537A/en unknown
- 2019-12-19 SG SG11202106348QA patent/SG11202106348QA/en unknown
- 2019-12-19 AU AU2019403323A patent/AU2019403323A1/en active Pending
- 2019-12-19 BR BR112021011750-4A patent/BR112021011750A2/en unknown
- 2019-12-19 CA CA3123598A patent/CA3123598A1/en active Pending
- 2019-12-19 US US16/721,102 patent/US11427813B2/en active Active
- 2019-12-19 WO PCT/US2019/067493 patent/WO2020132252A2/en active Application Filing
-
2021
- 2021-06-10 PH PH12021551372A patent/PH12021551372A1/en unknown
- 2021-06-17 IL IL284133A patent/IL284133A/en unknown
- 2021-07-15 CO CONC2021/0009297A patent/CO2021009297A2/en unknown
-
2022
- 2022-07-22 US US17/814,371 patent/US20220356458A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021011750A2 (en) | 2021-08-31 |
| IL284133A (en) | 2021-08-31 |
| PH12021551372A1 (en) | 2021-11-29 |
| EA202191735A1 (en) | 2021-11-24 |
| WO2020132252A2 (en) | 2020-06-25 |
| CN113544268A (en) | 2021-10-22 |
| CO2021009297A2 (en) | 2021-07-30 |
| JP2022515742A (en) | 2022-02-22 |
| WO2020132252A3 (en) | 2020-07-23 |
| EP3898960A2 (en) | 2021-10-27 |
| US11427813B2 (en) | 2022-08-30 |
| MX2021007552A (en) | 2021-08-11 |
| US20200199563A1 (en) | 2020-06-25 |
| CA3123598A1 (en) | 2020-06-25 |
| EP3898960A4 (en) | 2022-11-30 |
| AU2019403323A1 (en) | 2021-07-01 |
| US20220356458A1 (en) | 2022-11-10 |
| KR20210106537A (en) | 2021-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201820166D0 (en) | Therapeutic agents | |
| GB201820165D0 (en) | Therapeutic agents | |
| IL282794A (en) | Therapeutic methods | |
| GB201804255D0 (en) | Macrophage-based therapy | |
| IL284133A (en) | Human alpha-galactosidase variants | |
| IL252479A0 (en) | Human alpha-galactosidase variants | |
| GB201805816D0 (en) | Therapeutic agents | |
| GB201813876D0 (en) | Treatment | |
| GB201819853D0 (en) | Therapy | |
| GB201800546D0 (en) | Treatment | |
| CA187131S (en) | Casket | |
| GB2573210B (en) | Casket | |
| GB201807147D0 (en) | Therapeutic combination | |
| LT3597169T (en) | Sauna | |
| GB201918688D0 (en) | Improved human verification | |
| GB201820170D0 (en) | Therapeutic agents | |
| GB201820164D0 (en) | Therapeutic agents | |
| GB201820160D0 (en) | Therapeutic agents | |
| GB201820172D0 (en) | Therapeutic agents | |
| GB201820168D0 (en) | Therapeutic agents | |
| GB201820162D0 (en) | Therapeutic agents | |
| GB201914492D0 (en) | Skin Structure | |
| GB201811753D0 (en) | Therapeutic agents | |
| GB201811467D0 (en) | Therapeutic agents | |
| GB201819936D0 (en) | Therapeutic methods |